Skip to main content

Advertisement

Table 2 Response assessment

From: A phase II study of capecitabine and oxaliplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract

Assessment of overall response in target and non-target lesions Number of patients %
CR 1 2.4
PR 9 21.4
SD 13 31.0
PD 12 28.6
Unevaluable, target lesions not assessed 7 16.7
Total 42 100